Codis va acquérir le site de Catalent à Nottingham, au Royaume-Uni, afin de créer la première capacité européenne de séchage par atomisation de bout en bout

Codis, a global contract development and manufacturing organization (CDMO) specializing in spray drying and particle engineering solutions, has announced its acquisition of the Nottingham site from Catalent Pharma Solutions. The deal, valued at an undisclosed amount, is expected to close in the third quarter of 2026, pending customary closing conditions. This strategic acquisition aims to enhance Codis's capabilities in the development and small-scale manufacturing of solid oral dosage forms (OSD) and establish the most comprehensive integrated spray drying solution in Europe.

The Nottingham facility boasts over two decades of experience in the UK, focusing on the development of formulations and clinical supply. This site will significantly bolster Codis's existing operations, particularly its recently expanded GEA Pharma-SD® PSD-4 spray drying installation in Haverhill, UK. The combination of these two facilities is poised to create a robust offering that covers the entire process from development to clinical supply and commercial intermediates, ultimately leading to final oral dosage forms.

The acquisition aligns with Codis's strategy to strengthen its expertise in particle engineering, a critical component in the pharmaceutical sector, particularly for small molecule drug candidates that often face solubility challenges. The integration of the Nottingham site will allow Codis to provide a seamless transition from formulation development to compliant commercial production, thereby reducing risks associated with scaling up processes. This move is expected to enhance the company's portfolio of bioavailability enhancement solutions, catering to the increasing demand for efficient drug delivery systems.

In the broader context of the pharmaceutical industry, this acquisition reflects a growing trend towards consolidation among CDMOs as companies seek to enhance their capabilities and service offerings. The demand for integrated solutions in drug development and manufacturing is on the rise, driven by the need for faster and more efficient pathways to market. Codis's strengthened position in the European market through this acquisition may serve as a catalyst for further consolidation in the sector, as companies look to optimize their operations and meet the evolving needs of their clients.

Overall, the acquisition of Catalent's Nottingham site by Codis underscores the importance of strategic investments in enhancing operational capabilities within the pharmaceutical manufacturing landscape. As the industry continues to evolve, companies that successfully integrate advanced technologies and expand their service offerings are likely to emerge as leaders in the competitive CDMO market.